Loading organizations...
Medica Venture Partners operates as a venture capital fund focused on the healthcare and life sciences sectors. The firm invests in innovative companies across Israel, Europe, and the United States, targeting those developing advanced medical technologies, biotechnological solutions, and digital health applications. Its strategy emphasizes enterprises addressing critical global health challenges.
Established by experienced investors and medical professionals, the firm recognized a need for specialized capital and strategic support within healthcare innovation. This insight aimed to bridge the gap between scientific discovery and commercialization, accelerating development of groundbreaking solutions. This collective expertise guides its investment philosophy.
Medica Venture Partners partners with early to growth-stage companies within its target markets. The firm’s vision is to influence global healthcare's future, fostering transformative medical solutions. Ultimately, it aims to contribute to more efficient healthcare systems and enhanced public well-being.
Medica Venture Partners has 2 tracked investments across 1 company. The latest tracked deal is $15.0M Series D in Regentis Biomaterials in February 2016.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 11, 2016 | Regentis Biomaterials | $15.0M Series D | Haisco Pharmaceutical Group | Generali, SCP Vitalife Partners, Technion Innovation Opportunities Fund, Technion Research And Development Foundation |
| May 14, 2012 | Regentis Biomaterials | $10.0M Series C | — | Crossroad Fund, Royal DSM, SCP Vitalife Partners, Technion |
